|
**Overview**: MLC1 Hot Spot Mutation Panel**Introduction**: The MLC1 Hot Spot Mutation Panel is a diagnostic tool designed to screen for MLC1 mutations using whole blood samples. In India, megalencephalic leukoencephalopathy with subcortical cysts (MLC, Van der Knaap disease) is a rare autosomal recessive disorder (prevalence ~1 in 100,000-200,000, higher in certain communities due to consanguinity), presenting with macrocephaly, motor deterioration, and white matter changes on MRI. High morbidity from underdiagnosis in rural/low-SES children with progressive spasticity or seizures, limited genetic labs, delayed supportive care leading to wheelchair dependence or death. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for MLC1 Van der Knaap and Nalband hot spot mutations over 1-2 days with high accuracy, valuable for confirming diagnosis in suspected cases. This diagnostic falls under genetic disorder screening and targets children with macrocephaly, ataxia, or MRI findings, addressing accurate detection to guide genetic counseling and multidisciplinary care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular confirmation and reducing burden of rare neurogenetic diseases. Its whole blood-based approach ensures reliable mutation detection.**Other Names**: MLC1 Mut Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: MLC1 mutations identified 2000s; in India, reported in consanguineous families.**Purpose**: The test assesses 2 parameters including MLC1 Van der Knaap mutation to guide MLC screening, confirm diagnosis, inform counseling.**Test Parameters**: 1. MLC1 Van der Knaap Mutation, 2. MLC1 Nalband Mutation.**Pretest Condition**: No fasting required; patients should have macrocephaly or MRI changes.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on head growth, motor delay, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed MLC including progression, benefits of genetic confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive hot spot mutation confirms MLC, necessitating specialist input.**Specialist Consultation**: Pediatric neurologists should be consulted for management.**Additional Supporting Tests**: MRI brain, full MLC1 sequencing for confirmation.**Test Limitations**: Hot spot only; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Neurogenetic Studies India 2023. |
